Trial Profile
A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary) ; Vorinostat (Primary)
- Indications Carcinoid tumour; Lymphoma; Oesophageal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- 03 Nov 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 04 Sep 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 25 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.